About Us_ANBISON LAB

中

Contact number:

400 007 5658

Who We Are?

Anbison is a pharmaceutical company founded and managed by a team of domestic and international pharmaceutical experts. With a focus on the development, manufacturing, and commercialization of pharmaceutical preparations, the company is dedicated to developing complex generics that meet the strict quality and efficacy standards, as well as new drugs with therapeutic benefits. Anbison also prioritizes the global expansion of its products, leveraging expertise in industrial-scale production, streamlined manufacturing processes, and rigorous quality assurance systems. By driving down costs and enhancing drug accessibility, the company strives to deliver high-quality drugs to patients worldwide.

Who We Are?

Anbison is a pharmaceutical company founded and managed by a team of domestic and international pharmaceutical experts. With a focus on the development, manufacturing, and commercialization of pharmaceutical preparations, the company is dedicated to developing complex generics that meet the strict quality and efficacy standards, as well as new drugs with therapeutic benefits. Anbison also prioritizes the global expansion of its products, leveraging expertise in industrial-scale production, streamlined manufacturing processes, and rigorous quality assurance systems. By driving down costs and enhancing drug accessibility, the company strives to deliver high-quality drugs to patients worldwide.

19+ Year
18+ years in drug formulation & improved new drug development
60+ ANDA
60+ products were filed, 50+ products have been approved
20000+ ㎡
20,000+ ㎡ multi-dosage forms, sustained/controlled release, and long-acting injection production facilities

Founded in 2007 in Shanghai Caohejing Development Zone, Anbison initially operated as a contract research organization (CRO) from 2007 to 2015, offering drug R&D and international drug registration services to domestic pharmaceutical companies to assist them in entering international markets including the United States. In 2015, after implementing the Market Authorization Holder (MAH) system, the company became the nation's first R&D institution to obtain MAH status. Anbison possesses extensive expertise in the research and development (R&D) and manufacturing of modified-release drugs.

Over the past decade, Anbison has filed 60+ generic drugs in the United States and China, of which 50+ has been approved, including 30 owned by Anbison itself. Anbison is committed to delivering high-quality generic and new drugs that comply with international quality standards to patients in China and worldwide. We operate a unified production line and adhere to consistent quality standards to supply the Chinese, U.S., and European markets.

Anbison R&D lab: located at No. 18 Qujing Road, Xuhui District, Shanghai, China, equipped with advanced small scale, medium-scale and analytical laboratories for drug formulations development.

Manufacture site: situated in China Medicine City, Taizhou, Jiangsu Province, this facility spans over 20,000 square meters and is equipped with advanced equipment for manufacturing sustained-release and controlled-release solid preparations, including microsphere-coated tablets, matrix tablets, suppositories, and long-acting liposome injection products.
In addition to its own manufacturing facility, Anbison collaborates with multiple CMOs, including Hangzhou Minsheng Binjiang Pharma., CSPC OUYI Pharmaceutical Co., Ltd., Qingdao BAHEAL Pharmaceutical Co., Ltd., Tianjin Tasly Sants Pharmaceutical Co., Ltd., to deliver comprehensive high-quality services for domestic and overseas patients.

Mission and Vision

Mission:

Development and Manufacture of high quality and affordable generic drug as well as innovative drug for both Chinese and foreign patients.

Vision：

To become one of China's outstanding pharmaceutical companies, focused on product & process innovation and quality improvement.

Board of Directors

Advisory Board

Jifeng Lei

Founder, CEO

Master of Chemical Engineering, Xi'an Jiaotong University; EMBA.

Visiting Professor, Peking University & Yeehong Business School.

30+ years in formulation engineering, manufacturing, and R&D, with a robust theoretical foundation and practical expertise in the industrialization process design of formulation.

1988-1999, Xi'an Janssen, successively serving as Engineering Manager and Production Director.

2000–2003, Sanofi (Hangzhou), Plant Director.2003–2006, GSK (Tianjin), Plant Director. 2007, Founded Anbison Lab. Co., Ltd.

Team Leader of the Three Technical Guidelines for the 2010 GMP Version.

2015-2016, Chairman of ISPE China.

Ronggen Jin

Formula Specialist, Director
Zhihang Lei

VP, Director
Sales & Marketing Director
Yuqi Zhu

Director
Kuang He

Director

Dr. GARTH BOEHM

Formula and RA Specialist
Scientific Committee member

Company History

- Anbison was established in Shanghai.
- The formulation laboratory was completed.
- Held The First International Generic Drug Forum.
- Participated in the revision of Good Manufacturing Practice for Pharmaceutical Products (GMP) (2010 Edition)‌
- Helped the first client pass the U.S. cGMP certification.
- Help the first client get drug approval in the U.S.
- Anbison received the special funds by Shanghai Science and Technology Innovation.
- Montelukast Sodium Chewable Tablets (4mg/5mg) got approval in the U.S.
- Montelukast Sodium Tablet（10mg）got approval in the U.S.
- Anbison was recognized as a High-Tech Enterprise.
- Bupropion Hydrochloride Extended-Release Tablets got approval in the U.S.
- The company secured a multi-million-dollar investment from its strategic partner, Yongtai Technology (SZ:002326).
- Participated in the National Major New Drug Creation Program.
- Independently undertook 2 projects under the National Major New Drug Creation Program.
- Montelukast Sodium Chewable Tablets(4/5mg) and Montelukast Sodium Tablet (10mg) get approval in China.
- Montelukast Sodium Tablet (10mg) won the bid in the National "4+7" Volume-Based Procurement of Drugs.
- Anbison became as the Nation’s first R&D company to obtain the MAH status.
- Completed a strategic investment of tens of millions in Zhejiang Jiangbei Pharmaceutical Co., Ltd.
- Montelukast Sodium Tablets (10mg ) won bids in 13 provinces under the 25-Province Alliance Volume-Based Procurement.
- Montelukast Sodium Tablets & Montelukast Sodium Chewable Tablets are included in the High-Tech Achievement Transformation Project.
- Undertook two projects under the National Major New Drug Creation Program during the 13th Five-Year Plan period.
- Tamsulosin Hydrochloride Capsules got approval in the U.S.
- Tamsulosin Hydrochloride Capsules got approval in China.
- Tamsulosin Hydrochloride Capsules and Montelukast Sodium Chewable Tablets won the bid in the third batch of National Volume-Based Centralized Procurement of Drugs.
- Taizhou facility was completed and put into operation.
- U.K. subsidiary was established.
- The company's project was honored as one of the "Top Ten" in the 2019 Shanghai High-Tech Achievements Transformation.
- Jiangsu Anbison obtained “Pharmaceutical Production License”.
- Felodipine Sustained Release Tablets became the first generic drug to pass the consistency evaluation and obtain approval from the NMPA.
- Anbison ranked 6th in the “2020 China Pharmaceutical Industry Growth Enterprise Top 50”.
- Carbamazepine Extended Release Tablets got approval in the U.S.
- Awarded the title of the first batch of "Zhangjiang Star" by Shanghai Technology Venture Capital (Group) Co., Ltd.
- iangsu Anbison passed the on-site GMP compliance inspection for tablets.
- Won the 3rd “Xuhui District Government Quality Award”.
- Jiangsu Anbison completed the construction of the sterile pharmaceutical preparations project.
- Jiangsu Anbison Phase I project was put into production, and Phase II project achieved completion.
- Taizhou facility passed the U.S. FDA cGMP on-site inspection.
- The new R&D and office building in Shanghai was officially put into use.
- The company's R&D system was awarded the title of "Xuhui District Technology Center"
- Montelukast Sodium Tablets (10mg *10 tablets) manufactured by Jiangsu Anbison was officially launched.
- Jiangsu Anbison started the construction of the Phase II sterile pharmaceutical preparations project.
- The company's R&D system has been recognized as a "Shanghai Technology Center."
- Jiangsu Anbison and Sandoz China forged Strategic Partnership.
- Agomelatine tablets, the first product held by Jiangsu Anbison, won the bid in the National Volume-Based Centralized Procurement of Drugs.
- The modified new drug Levetiracetam extended-release Granule got approval in China and it was marketed as RLD brand Keppra by NeuroGen Pharma.
- Benidipine Hydrochloride Tablets and Agomelatine Tablets won the bid in the eleventh batch of National Volume-Based Centralized Procurement of Drugs；Mesalazine Enteric-coated Tablets（Gsatro Resistant Prolonged Release) won the ‌Guangdong Alliance Centralized Procurement of drugs.
- Jiangsu Anbison’s Mesalazine Suppositories, as the first product to pass the Generic Drug Consistency Evaluation‌, has partnered with Ethypharm to jointly expand the gastrointestinal treatment market.